Injectable Treatment Corrects Breathing Disorders in Horses
LEXINGTON, KY, April 7, 2016 CrossCoat Medical LLC. (CCM) is pleased to announce the proposed medical device (CCM-D) has shown positive results in a recent pilot in vivo (equine) large animal study.
“Our proposed medical device (CCM-D) involves injections of a protein crosslinker to reduce palatal vibrations and airway blockages due to excessive tissue compliance or floppiness. The matrix crosslinking bonds are formed rapidly offering an almost immediate treatment effect”, says Dr. Hedman.
“Our National Institutes of Health funded testing was successful in demonstrating the potential effectiveness of genipin crosslink augmentation in a pilot study with a living animal model – horses with an exercise-induced soft-palate displacement and snoring disorder (DDSP). The single dose level that was evaluated in the pilot horse study demonstrated varying levels of effectiveness in the DDSP horses with two of the three horses apparently fully “cured” by the treatment. The overall goal of these studies is to provide information and data for an inexpensive, immediately effective, safe and lasting means to eliminate severe snoring and obstructive sleep apnea in humans.”
“Prior to and following the soft palate injections, dynamic endoscopic examinations were completed to confirm the DDSP diagnosis and to evaluate the effectiveness of the treatment. In addition, audio recordings were taken while each horse was exercising to document the frequency and loudness of the snoring, palate displacement, and gaps in breathing. Each horse was recorded for ten minutes while cantering before and two weeks after the treatment. Prior to the injections, all three DDSP horses would stop breathing for a few seconds when their palates were displaced (from underneath the epiglottis into the nasal passage). After injections, the breathing had a smooth and steady rhythm, without any large breathing gaps. Overall, the pilot in vivo study demonstrated that injecting the crosslinking solution is feasible, safe, and effective in reducing snoring loudness and preventing soft palate displacements. All three of the DDSP horses showed a reduction in snoring loudness and an increase in exercise performance. Two of the three horses no longer experienced airway obstruction”, says Dr. Hedman.
According to Dr. Tom Hedman, CSO of CrossCoat Medical and a leading researcher in soft-tissue biomechanics, “The device forming technology being developed by CCM is designed to immediately strengthen and stabilizes the tissue upon application. Through the addition of numerous, permanent, chemical bonds, the device significantly stabilizes the tissue, reducing floppiness and increasing durability for immediate and long-term treatment of common problems such as snoring and OSA (obstructive sleep apnea)”.
Snoring can affect the quality of sleep, increase risk of stroke, and lead to obstructive sleep apnea syndrome (OSAS) where the airway is physically obstructed for periods of time during sleep. The reported prevalence of snoring in the U.S. population varies widely, ranging from 14-48%, and the incidence of OSAS is estimated to be between 2-24%. Current treatment methods for snoring include over the counter medications, oral devices, patient administered interventions such as weight loss or posture adjustments, and nasal dilators. Treatment options for the more serious condition of OSAS usually starts with the above treatment modalities but can also include continuous positive airway pressure (CPAP) therapy, or surgical options.
CCM is located on the University of Kentucky’s Coldstream Research Campus in the heart of the Kentucky Bluegrass Region. Coldstream provides ILS with a connection to students, researchers, and resources at the University of Kentucky.